Published in Int J Radiat Oncol Biol Phys on April 02, 1993
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med (1996) 6.49
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol (2004) 4.46
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology (1994) 2.51
Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2000) 2.32
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res (2001) 2.28
Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology (1994) 2.12
Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol (1991) 2.08
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Consent for a minor's abortion. N C Med J (1989) 2.03
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg (1983) 1.86
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg (2000) 1.82
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg (1991) 1.81
Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. Int J Radiat Oncol Biol Phys (2000) 1.75
Radiation therapy for brain metastases. Ann Neurol (1980) 1.68
Increasing incidence of primary brain lymphoma in the US. Cancer (1988) 1.68
Glioma classification: a molecular reappraisal. Am J Pathol (2001) 1.65
Telomerase activity in human brain tumours. Lancet (1995) 1.64
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol (1993) 1.62
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol (1998) 1.61
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59
Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol (1998) 1.56
Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med (1997) 1.54
Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys (1992) 1.54
Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res (1995) 1.52
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol (1999) 1.52
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys (1992) 1.51
Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol (1985) 1.51
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology (2011) 1.48
Intravenous acyclovir in acute herpes zoster infection. J Infect (1983) 1.47
PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci (2001) 1.47
Measuring bias in uncontrolled brain tumor trials--to randomize or not to randomize? Can J Neurol Sci (1997) 1.43
Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol (1979) 1.42
Oligodendroglioma. Cancer Invest (1996) 1.39
Physician-assisted suicide and advance directives concerning life support. N C Med J (1993) 1.39
Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res (2001) 1.38
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol (1990) 1.35
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol (1998) 1.32
Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys (2000) 1.32
Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg (1989) 1.27
Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res (1982) 1.25
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res (1997) 1.24
Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol (1988) 1.23
Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys (1993) 1.20
Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys (2003) 1.20
Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys (1999) 1.18
Mental neuropathy from systemic cancer. Neurology (1981) 1.18
Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun (1985) 1.16
Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci (1998) 1.15
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol (1981) 1.15
Identification of glial filament protein and vimentin in the same intermediate filament system in human glioma cells. Proc Natl Acad Sci U S A (1984) 1.14
Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol (1994) 1.14
Monoclonal antibodies to three widely distributed human cell surface antigens. Hybridoma (1983) 1.14
Studies on the use of "prophylactic" intrathecal amethopterin in childhood leukemia. Blood (1970) 1.14
p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst (1994) 1.13
Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol (1997) 1.13
Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med (1995) 1.13
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology (1991) 1.13
An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. J Cell Biol (1983) 1.11
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res (2001) 1.09
Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med (1980) 1.09
Sarcoma of bone and soft tissue following treatment of Hodgkin's disease. Cancer (1984) 1.07
Primary cerebral fibrosarcomas. Clinicopathologic study and review of the literature. Cancer (1993) 1.06
Longitudinal study of the standard electrocardiogram in the healthy premature infant during the first year of life. Am J Cardiol (1973) 1.06
Postoperative contrast enhancement in patients with brain tumor. Ann Neurol (1985) 1.05
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol (2001) 1.04
Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg (1994) 1.03
The adult respiratory distress syndrome. Cell populations and soluble mediators in the air spaces of patients at high risk. Am Rev Respir Dis (1987) 1.02
The management of desmoid tumors. Int J Radiat Oncol Biol Phys (1993) 1.02
Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med (1992) 1.01
Tumor necrosis factor. Alpha and beta subtypes appear in circulation during onset of sepsis-induced lung injury. Am Rev Respir Dis (1991) 1.01
Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol (1999) 1.01
Significant prolongation of hamster liver transplant survival in Lewis rats by total-lymphoid irradiation, cyclosporine, and splenectomy. Transplantation (1990) 1.01
The spectrum of mild X-linked recessive muscular dystrophy. Arch Neurol (1977) 1.00
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1994) 1.00
Clinical application of PET for the evaluation of brain tumors. J Nucl Med (1991) 0.99
Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys (1998) 0.99
Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol (2005) 0.99
Tumor necrosis factor-alpha blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation. J Clin Invest (1993) 0.98
Soluble E-selectin levels in sepsis and critical illness. Correlation with infection and hemodynamic dysfunction. Am J Respir Crit Care Med (1997) 0.98
Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol (1980) 0.97
Xenograft survival in two species combinations using total-lymphoid irradiation and cyclosporine. Transplantation (1987) 0.96
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology (1999) 0.95
Glioblastoma multiforme after radiotherapy for acromegaly. Neurosurgery (1983) 0.94
Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res (1994) 0.94